Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17957732 | 1.00 | RARA (0.39) | RARARARBRARGHPGDTSHR | |
| SCHEMBL17991513 | 0.91 | ALDH1A1 (0.37) | HPGDTSHRSMN1; SMN2HRH3RAB9A | |
| SCHEMBL17957556 | 0.89 | HDAC6 (0.39) | HPGDTSHRSMN1; SMN2PRMT5 | |
| SCHEMBL17957557 | 0.89 | HDAC6 (0.39) | HPGDTSHRSMN1; SMN2PRMT5 | |
| SCHEMBL17957683 | 0.87 | RARA (0.40) | RARARARBRARGHPGDTSHR | |
| SCHEMBL17957686 | 0.87 | RARA (0.40) | RARARARBRARGHPGDTSHR | |
| SCHEMBL17957477 | 0.86 | RARA (0.41) | RARARARBRARGHPGDTSHR | |
| SCHEMBL17957476 | 0.86 | RARA (0.41) | RARARARBRARGHPGDTSHR | |
| SCHEMBL17957838 | 0.84 | ROCK2 (0.39) | HPGDTSHRSMN1; SMN2PRMT5 | |
| SCHEMBL17991515 | 0.82 | ALDH1A1 (0.45) | HPGDTSHRSMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2021-01-14 | — | — | US | disclosed |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-20 | — | — | US | disclosed |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| WO-2016126722-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RARA 1843/4885RARB 1910/4885RARG 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.